A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer.

Trial Profile

A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms A-taxel
  • Most Recent Events

    • 09 Jan 2014 According to ClinicalTrials.gov [NCT01069796] planned end Date changed from 1 Dec 2015 to 1 Jun 2014.
    • 09 Jan 2014 According to ClinicalTrials.gov [NCT01069796] study status changed to discontinued.
    • 14 Dec 2013 Results presented at the 36th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top